Tozuleristide - Blaze Bioscience
Alternative Names: BLZ-100; Chlorotoxin conjugated to indocyanine green dye - Blaze Bioscience; Chlorotoxin-indocyanine-green-conjugate; CyTP-007; Tumor Paint BLZ-100; Tumour paintLatest Information Update: 13 Dec 2023
At a glance
- Originator Blaze Bioscience
- Developer Blaze Bioscience; Seattle Children's Hospital
- Class Biological toxins; Drug conjugates; Imaging agents; Indoles; Peptides
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III CNS cancer
- Phase I/II Mouth neoplasm; Squamous cell cancer
- Phase I Head and neck cancer
- Preclinical Lung cancer
- No development reported Breast cancer; Glioma; Skin cancer; Soft tissue sarcoma
Most Recent Events
- 29 Nov 2023 University of Washington in collaboration with Blaze Bioscience reinitiates a phase I/II trial in Mouth neoplasm (Diagnosis) in USA (IV) (NCT05316688)
- 31 Oct 2023 University of Washington in collaboration with Blaze Bioscience suspended phase I/II trial in Mouth neoplasm (Diagnosis) in USA (IV) due to staffing (NCT05316688)
- 16 Oct 2023 Phase-I/II clinical trials in Mouth neoplasm (Diagnosis) in USA (IV) as of October 2023 (NCT05316688)